ExCellThera_RGB.png
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
March 15, 2022 08:04 ET | ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
ExCellThera_RGB.png
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
July 13, 2021 08:05 ET | ExCellThera
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...
ExCellThera_RGB.png
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
May 07, 2019 08:05 ET | ExCellThera
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...